|Bid||107.52 x 900|
|Ask||108.71 x 800|
|Day's range||107.55 - 108.80|
|52-week range||101.24 - 142.60|
|Beta (5Y monthly)||0.70|
|PE ratio (TTM)||22.53|
|Earnings date||18 Oct 2022 - 24 Oct 2022|
|Forward dividend & yield||1.88 (1.72%)|
|Ex-dividend date||14 Jul 2022|
|1y target est||127.91|
This week, in legal news Yahoo Finance is following stalled legislation that would have reined in Big Tech; lawsuits piling up against formula maker Abbott; and a simmering legal feud between Twitter and Tesla CEO Elon Musk.
Abbott Laboratories' growth looks much less impressive after removing sales from COVID-19 diagnostics.
Raymond James Healthcare Policy Analyst Chris Meekins joins Yahoo Finance Live to discuss the expectations for the Manchin-Schumer deal, expanding regulation on drug prices, out-of-pocket Medicare expenses, and the outlook for pharmaceutical company earnings.